The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.

The ADC market presents opportunities across cancer types, payloads, targets, products, users, and countries. Significant growth prospects exist in this multi-billion-dollar industry, offering ...

The emerging cancer therapy market, driven by breakthroughs like CAR-T cells and checkpoint inhibitors, offers significant growth opportunities. Companies advancing these technologies stand to benefit ...

North America remains the dominant market, driven by high healthcare expenditure, advanced R&D infrastructure, and early adoption of innovative therapies. The region’s focus on oncology and ...